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 ABSTRACT 
Aim: To assess the efficacy of intravitreal Ranibizumab for the treatment of new onset 
inflammatory choroidal neovascularization (iCNV), including both uveitic and 
idiopathic CNV. 
Methods: Single-centre, open label, non-randomised phase IIb clinical trial. Patients 
fulfilling strict entry criteria of new onset iCNV were given monthly intravitreal 
Ranibizumab injections for 3 months. Thereafter, re-treatment was based on evidence of 
persisting activity. All patients completed trial follow-up. Optical coherence 
tomography (OCT) and best corrected visual acuity (BCVA) were performed at every 
visit. Fluorescein angiography was performed at baseline, months 4, and 12. Descriptive 
analysis and Wilcoxon non-parametric test were performed for analysis. 
Results: Fifteen patients, 10 females with a mean age of 48.8 (range 24 to 85) years 
were included in the study. The mean number of injections was 4.33 (range 3 to 7). 
There was a statistically significant difference in the BCVA at month 4 (p=0.001) and at 
month 12 (p=0.001) compared with baseline. The mean gain in BCVA at month 4 
compared with baseline was 20±15.36 letters (mean ± SD), and at month 12 was 
21±16.97 letters. There was a statistically significant difference in the mean central 
subfield thickness (CST) at baseline versus month 4 (p=0.003) and month 12 (p=0.001). 
Conclusions: Patients gained vision (mean of 21 letters at 12 months) and showed 
reduced CST. These results support the continued use of Ranibizumab in the treatment 
of iCNV. 
 
KEY WORDS: Choroidal neovascular membrane; Inflammatory; Uveitis; 
Idiopathic; Ranibizumab.
  
INTRODUCTION 
 
Ocular Inflammatory mediated angiogenesis may manifest as choroidal 
neovascularization (CNV) in a variety of uveitic entities and in young patients with 
idiopathic CNV. In a recent large cohort multicentre study involving 15,137 patients 
with uveitis, the sight-threatening complication of CNV was present in 2.0% of patients 
with posterior segment intraocular inflammation (PSII – intermediate, posterior and 
panuveitis) in at least one eye at presentation. The cumulative 2-year incidence of CNV 
for those patients with PSII who did not have a CNV at presentation was 2.7% [1]. 
The incidence of a CNV is associated with significant loss of vision, with around 2-
lines loss of visual acuity (VA) at presentation of CNV having been reported in PSII [1]. 
A corollary is that idiopathic CNV is an early manifestation of inflammatory 
chorioretinal disease [2]. This is corroborated by findings that whilst the global 
assessment of inflammatory activity and cell count in the anterior chamber is associated 
with increased risk of incident CNV, vitreous haze and vitreous cells were not. 
Furthermore, the development of new CNV is not always associated with clinically 
manifest intraocular inflammation [1]. 
Treatment of PSII-associated, inflammatory CNV (iCNV) have included laser 
photocoagulation [3], surgery [4], systemic or periocular steroids [5], systemic 
immunomodulatory treatment (IMT) [6], photodynamic therapy (PDT) [7], or a 
combination of the latter therapies [8]. There are also some anecdotal reports of the use 
of other therapeutic agents such as intravitreal methotrexate [9] and oral sirolimus [10]. 
The successful introduction of anti-VEGF drugs for the treatment of age-related and 
myopic CNV has led to an approach to consider anti-VEGF treatment for iCNV alone 
or as an adjunct to those patients already on systemic IMT. Several retrospective studies 
in patients with iCNV have shown good outcomes with the use of Bevacizumab and 
Ranibizumab [11-17], and more recently in a prospective study with Bevacizumab [18]. 
 
Given the supportive but limited evidence of efficacy, the aim of this phase IIb trial was 
to provide evidence of efficacy of intravitreal Ranibizumab for the treatment of new 
onset iCNV secondary in patients with uveitis or presenting with idiopathic iCNV. The 
primary endpoint was the proportion of patients losing less than 15 ETDRS letters of 
BCVA from baseline at months 4 and 12. 
 
MATERIALS AND METHODS 
 
Patients 
Patients over 18 years old presenting with new active inflammatory CNV, and fulfil the 
inclusion criteria and exclusion criteria (Table 1) were eligible for participation in the 
study. The study was performed at the Clinical Research Unit, Bristol Eye Hospital, 
where patients were recruited from the Regional Ocular Inflammation Service. 
Patients taking oral corticosteroids and/or systemic IMT at the time of being included in 
the study, continued on treatment, but the dose was not altered whilst receiving 
Ranibizumab therapy. 
All subjects signed a consent form to participate in the study. The study received UK 
National Health Service (NHS) research ethics committee approval (NHS REC 
reference: 09/H0106/5; EudraCT: 2008-007476-19). 
 
Study design 
The study was an open label non-randomised Phase IIb trial to evaluate the therapeutic 
response of intravitreal Ranibizumab on the treatment of inflammatory and idiopathic 
CNV. Patients were given monthly intravitreal Ranibizumab (0.5mg Lucentis® in 
0.05ml) injections for 3 months. Thereafter, re-treatment was based on clinical evidence 
of persisting activity (using optical coherence tomography (OCT), best-corrected VA 
(BCVA) and fundus fluorescein angiography (FFA)). The patients were reviewed on a 
monthly basis for a total of 13 visits. All adverse events were reported. 
OCT and BCVA were performed at every visit. BCVA was expressed as letter score 
(Early Treatment Diabetics Retinopathy Study (ETDRS) notation). FFA (Topcon TCR 
50IX) was performed at baseline, months 0, 4, 12, and as required at other visits. 
Central subfield thickness (CST) was determined by OCT imaging (Cirrus HD-OCT, 
Carl Zeiss Meditec AG, Germany), corresponding to the retinal thickness of the central 
1 mm area as described in the ETDRS fields. 
CNV size and area of leakage were determined manually with the IMAGEnet 2000 
v2.57 software at month 0, 4, and 12 by one medical retina specialist. 
 
Outcomes 
The primary outcome measure was defined as the proportion of patients who lost less 
than 15 letters of BCVA from baseline at months 4 and 12. Secondary outcome 
measures were the mean change from baseline in BCVA at months 4 and 12, mean 
change from baseline in CST measured by OCT at 4 and 12 months, mean change from 
baseline in total size of CNV complex at 4 and 12 months, change in area of leakage at 
4 and 12 months and number of treatments required with Ranibizumab.  
 
Statistical analysis 
In patients where data were not available for a particular visit, no substitution of values 
was performed. 
Probabilities of events after intravitreal Ranibizumab were presented as survival curves 
using the Kaplan Meier method. Descriptive analysis and Wilcoxon non-parametric test 
were performed for analysis. A p-value <0.05 was considered as statistically significant. 
Microsoft Excel 2011 (Microsoft Corporation, Redmond, US) and SPSS 20.0 (SPSS 
Inc., Chicago, US) were used for analysis. All values were expressed as the mean ± 
standard deviation (SD). 
 
RESULTS 
 
Fifteen patients were included in the study. There were 10 females (66.7%) and 5 males 
(33.3%) with a mean age of 48.8 ± 20.5 (mean ± SD) years, range 24 to 85 years. All 
the patients completed one-year follow-up. The right eye (OD) was involved in 10 cases 
(66.7%) and the left eye (OS) in 5 cases (33.3%). The most common diagnosis was 
uveitic CNV in 9 cases (60.0%). Up to 4 patients (26.7%) were treated with IMT at the 
beginning of the study and as per protocol continued without subsequent change to dose 
throughout the study period. Table 2 summarizes the patients’ demographics and 
aetiology of the CNV. 
 
Mean change from baseline in BCVA at months 4 and 12  
100% of patients avoided loss of more than 15 letters of vision in the treated eye. The 
Wilcoxon non-parametric test for related-samples showed a statistically significant 
difference in BCVA at month 4 (p=0.001) and at month 12 (p=0.001) compared with 
baseline. The mean BCVA was 53 ± 14.56 letters (mean ± SD), 73 ± 12.21 letters 
(mean ± SD), and 74 ± 15.02 letters (mean ± SD) at baseline, 4 months and 12 months 
respectively. The mean gain in BCVA at month 4 compared with baseline was 20 ± 
15.36 letters (mean ± SD), and at month 12 was 21 ± 16.97 letters (mean ± SD). Figure 
1 shows the mean increase in letters from baseline (at month 0) at follow-up. Seven out 
of 15 patients (46.7%) improved 15 or more letters in the BCVA at month 4 compared 
with baseline BCVA and 10 (66.7%) at month 12. Figure 2 shows the Kaplan-Meier 
curves for the time to increase 15 letters in the BCVA. The median time to increase 15 
letters in the BCVA was 5.07 months (95% confidence interval: 2.67 - 7.46). Fourteen 
out of 15 patients (93.3%) had a stable or improved BCVA at month 12 in comparison 
with baseline. 
 
Mean change from baseline in CST measured by OCT at months 4 and 12 
CST as measured by OCT demonstrated a statistically significant difference in the mean 
CST at baseline versus month 4 (p=0.003) and month 12 (p=0.001) with the Wilcoxon 
non-parametric test for related-samples. The mean CST was 395 ± 93 µm, 282.60 ± 
57.79 µm and 252 ± 81 µm at baseline, 4 months and 12 months respectively. The mean 
change in the CST in comparison with the baseline measurement at month 4 was -112 ± 
111 µm and at month 12 was -143 ± 109 µm. Figure 3 shows the mean change in 
macular thickness from baseline during the follow-up. 
 
Mean change from baseline in total size of CNV and area of leakage at 4 and 12 
months 
The mean size of the CNV complex at baseline was 1.37 ± 1.27 mm2. There was a mean 
change of the CNV complex at month 4 was of -0.15 ± 1.21 mm2 and -0.67 ± 0.97 at 
month 12 with respect to baseline measurements. The mean area of leakage at baseline 
was 1.88 ± 1.42 mm2. The mean change in the area of leakage at month 4 was -0.72 ± 
1.02 mm2 and -1.12 ± 1.06 mm2 at month 12. 
 
Number of treatments required with Ranibizumab 
The mean number of Ranibizumab injections that patients received during the 12 
months of follow-up was 4.33 ± 1.40 (mean ± SD) injections (range 3 to 7 injections). 
Particularly the mean number of injections during the 12-months follow-up for the 
group of idiopathic CNV was 4 ± 1.10 (mean ± SD) and 4.56 ± 1.59 (mean ± SD) 
injections for the group of uveitic CNV. In cases where further injections were needed 
after the loading phase, the mean time for the 4th injection was 2.51 ± 2.34 (mean ± SD) 
months. A total of 6 patients (40%) did not need any further injection after the loading 
dose, which included 4 uveitic CNV (44.4% of uveitic CNV) and 2 idiopathic CNV 
(33.3% of idiopathic CNV). 
 
Adverse events 
No adverse events or complications presumed related to the study treatment were 
observed during the study period. One patient reported increase in floaters at month 1, 
but had no evidence of vitritis on examination. 
 
DISCUSSION 
 
All patients avoided loss of more than 15 letters of vision, and there was a mean 
increase of 21 letters after treatment at month 12.  This study has provided trial 
evidence to support the current practice and on-going use of Ranibizumab in the 
treatment of inflammatory CNV. In addition, the treated eyes showed a decrease in the 
CST and in the size and leakage of CNV complex at month 4 and 12, supporting the 
functional improvement noted. 
As the design of this phase IIb trial end expected low recruitment, given prevalence of 
iCNV, the approved protocol was not designed to recruit to permit subsequent 
determination of differential responses or not between the classes of iCNV (idiopathic 
versus uveitic CNV). There remains nonetheless in common to both subgroups an 
inflammatory mediated drive of the iCNV to validate and support our approach [2 19].  
Patients were enrolled following a strict trial inclusion and exclusion criteria.  Cases of 
inflammatory CNV with presence of intraretinal fluid only, for example, were excluded, 
leading to potential ascertainment bias.  
 
Ranibizumab was approved in 2006 for the Food and Drug Administration for the 
treatment of neovascular age related macular degeneration (AMD). This approval was 
supported mainly in the outcomes of two pivotal phase III clinical trials: the ANCHOR 
and MARINA studies [20 21]. In these studies the Ranibizumab treatment group, the 
0.5 mg dose, achieved an improvement of 11.3 and 7.2 letters with respect to baseline at 
24 months [20 21]. The mean increase in letters in this study at month 12 was 21 letters, 
infers a superior outcome for the treatment of inflammatory CNV with Ranibizumab 
and is supported by similar good outcomes in retrospective reports for the treatment 
with Ranibizumab and Bevacizumab in inflammatory CNV. Some studies have 
demonstrated an increase of more than 3 lines after treatment [11-17]. The implication 
therefore from the positive results is that in presence of inflammation there remains a 
VEGF drive [22]. However, there are only a few histopathological studies and there is a 
lack of good animal models for inflammatory CNV to ascertain and dissect mechanisms 
at play.  Nevertheless in the few studies that have been undertaken, one notable finding 
was a significant expression of CXCR4 in the vascular network of inflammatory CNV 
[23]. CXCR4/SDF-1 axis is implicated in mTOR- mediated angiogenesis and 
pathological neovascularisation and expressed on RPE supporting the use of 
immunosuppression to reduce inflammatory CNV [24]. 
The specific role of inflammation in the pathogenesis of idiopathic and inflammatory 
CNV is also supported from other histological studies and the response observed 
following treatment of inflammatory CNV with immunosuppressive agents [5 6 9 10]. 
Before anti-VEGFs were available, corticosteroids were the first-line treatment for 
inflammatory CNV, and in particular corticosteroids in addition to photodynamic 
therapy were more effective than photodynamic therapy alone [25]. Similarly the 
combination of high dose of systemic steroids in combination with mycophenolate 
mofetil showed good control of iCNV, with improved in VA and stabilization of the 
CNV complex size [6]. In this study, to assess the effect of Ranibizumab alone on the 
CNV, we purposefully did not alter any immunomodulatory treatment during the 12 
month follow-up, where appropriate. 
Regarding the CNV complex size and area of leakage, better results than AMD-related 
CNV were achieved in this study. In the MARINA trial at month 12 in the 0.5mg 
ranibizumab-treated group there was a decrease in the area of leakage, and stabilisation 
but not a reduction in the lesion size [21]. In the ANCHOR study, reduction in leakage 
was also achieved in the 0.5mg ranibizumab-treated group, but there was no reduction 
in the area of the overall CNV complex. Only when the classic CNV component alone 
was assessed was there some reduction in CNV size demonstrated ( -0.67 mm2 ± 1.10 at 
12 months) [20]. 
The mean number of injections in the previously reported series for Bevacizumab in 
iCNV was around 2 injections (range 1-4.25) and around 3 injections (range 1-4) in the 
case of Ranibizumab [22]. There was a higher number of injections utilised in this trial 
(mean of 4.33 injections). This is likely to be related to the use of the loading doses and 
our strict follow up regimen [11 22].  
 
Although this study has limitations inherent to small phase IIb trials where definitive 
evidence of efficacy cannot be determined with small numbers of patients and in this 
trial, the lack of a control group, there nonetheless remains further proof of concept to 
support the use of Ranibizumab alone (without additional increase in the baseline IMT). 
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TABLE 1 
Inclusion criteria 
Patients with newly presenting idiopathic and inflammatory choroidal neovascularisation with: 
 Best-corrected ETDRS notation VA in the study eye between 73-24 letters. 
 CNV lesion of any type in the study eye with the following characteristics as determined by fluorescein 
angiography. 
 The lesion must be ≤5400 microns in greatest linear dimension. 
 No subfoveal atrophic change, no subfoveal fibrosis. Area of fibrosis less than or equal to 50% of total 
lesion area. 
 For occult with no classic CNV, the lesion must have presumed recent disease progression as assessed 
by the Investigator and defined as having at least one of the following criteria: 
 Blood associated with the lesion at baseline. 
 ≥10% increase in the greatest linear dimension as assessed by fluorescein angiography in the 
previous 3 months. 
 Loss of VA in the previous 3 months defined as either ≥5 letters logMAR vision as determined by 
protocol refraction and protocol measurement or 2 or more lines using a Snellen chart by standard 
examination. 
 Presence of subretinal fluid on OCT 
 Patients over the age of 18 
Exclusion criteria  
 Prior treatment with transpupillary thermotherapy, thermal laser, or PDT in the study eye. 
 Treatment with verteporfin in the non-study eye less than 7 days preceding Day 0. 
 Previous participation in a clinical trial (for either eye) involving anti-angiogenic drugs (Macugen®, 
Avastin®, anecortave acetate). 
 History of vitrectomy surgery, greater than mild non-proliferative diabetic retinopathy or any diabetic 
maculopathy, retinal vascular occlusions, glaucoma filtering surgery, or corneal transplant in the study eye. 
 Previous participation in any studies of investigational drugs within 1 month preceding Day 0 (excluding 
vitamins and minerals). 
 Subretinal haemorrhage in the study eye that involves the centre of the fovea, if the size of the haemorrhage is 
either >50% of the total lesion area or >1 disc areas in size. 
 Subfoveal fibrosis or atrophy in the study eye. Area of fibrosis > 50% of total lesion area. 
 Retinal pigment epithelial tear involving the macula in the study eye. 
 Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the 
opinion of the investigator, could either require medical or surgical intervention during the 12-month study 
period to prevent or treat visual loss that might result from that condition, or if allowed to progress untreated, 
could likely contribute to loss of at least 2 Snellen equivalent lines of best corrected visual acuity over the 12-
month study period. 
 Current vitreous haemorrhage in the study eye. 
 History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye. 
 Infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye. 
 Aphakia or absence of the posterior capsule in the study eye. 
 Previous violation of the posterior capsule in the study eye, unless it occurred as a result of YAG posterior 
capsulotomy in association with prior, posterior chamber intraocular lens implantation. 
 Spherical equivalent of the refractive error in the study eye demonstrating more than -8 dioptres of myopia or 
signs of pathologic myopia with a refraction of (-4)-(-8) dioptres. 
 For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative 
refractive error in the study eye cannot exceed -8 dioptres of myopia. 
 Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Day 0. 
 Uncontrolled glaucoma in the study eye (defined as intraocular pressure >30 mmHg despite treatment with 
anti-glaucoma medication). 
 Premenopausal women not using adequate contraception (considered effective means of contraception: 
surgical sterilisation; use of oral contraceptives; barrier contraception with either a condom or diaphragm in 
conjunction with spermicidal gel; an IUD; or contraceptive hormone implant or patch). 
 Pregnant and lactating women. 
 History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding 
giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or 
that might affect interpretation of the results of the study or render the subject at high risk for treatment 
complications 
 Current treatment for active systemic infection. 
 Recent stroke, or cardiac event, uncontrolled angina or hypertension. 
 History of allergy to fluorescein. 
 Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality to be analysed. 
 Inability to comply with study or follow-up procedures. 
 
Table 1.- Inclusion and exclusion criteria for the study. CNV: Choroidal 
neovascularization. ETDRS: Early Treatment Diabetic Retinopathy Study. VA: Visual 
acuity. PDT: Photodynamic therapy. 
TABLE 2 
PATIENT 
ID 
GENDER STUDY 
EYE 
AGE DIAGNOSIS Baseline 
VA 
IMT  NI 
1 Male OD 57 Idiopathic CNV 71 NO 6 
2 Male OS 47 Idiopathic CNV 42 YES* 3 
3 Female OD 72 Uveitic CNV 54 NO 3 
4 Female OS 26 Uveitic CNV 29 NO 6 
5 Female OS 20 Idiopathic CNV 47 NO 3 
6 Female OD 36 Idiopathic CNV 59 NO 4 
7 Male OS 48 Uveitic CNV 48 YES 6 
8 Female OD 37 Idiopathic CNV 71 NO 4 
9 Male OD 80 Uveitic CNV 64 YES 5 
10 Female OD 31 Uveitic CNV 48 NO 3 
11 Female OD 56 Uveitic CNV 54 NO 3 
12 Male OD 68 Uveitic CNV 73 YES 3 
13 Female OS 45 Uveitic CNV 69 NO 5 
14 Female OD 24 Idiopathic CNV 34 NO 4 
15 Female OD 85 Uveitic CNV 34 NO 7 
 
Table 2. Summary of patients’ demographics, diagnosis, visual acuity at baseline visit 
(expressed in ETDRS notation), concomitant use of oral immunomodulatory treatment 
during study follow-up and number of intravitreal injections. Uveitic CNV included as 
phenotypic diagnosis: 3 - punctate inner choroidopathy, 2  - serpiginous choroidopathy, 
1  - presumed ocular histoplasmosis syndrome, 1  - sarcoidosis, 1  - toxoplasma 
chorioretinitis, and 1 -multifocal choroiditis with panuveitis. OD: Right eye. OS: Left 
eye. CNV: Choroidal neovascularization. IMT: Immunomodulatory treatment. NI: 
number of injections. 
*: Patient number 2 was on oral IMT due to kidney transplant. 
FIGURE LEGENDS: 
 
Figure 1.- Line diagrams representing mean change in BCVA at each study visit with 
respect to baseline. Mean change in BCVA is represented as the number of letters 
(ETDRS notation). Error bars represent +/- 2 of the standard error. BCVA: Best 
corrected visual acuity. ETDRS: Early Treatment Diabetic Retinopathy Study. SE: 
Standard Error. 
 
 
 
Figure 2.- Kaplan Meier representation of the time to increase BCVA in 15 letters. 
BCVA: Best corrected visual acuity. 
 
 
Figure 3.- Line diagrams representing mean change in CST at each study visit with 
respect to baseline. Mean change in CST is represented in µm. Error bars represent +/- 2 
of the standard error. CST: Central subfield thickness. SE: Standard Error. 
 
 
